Cedars-Sinai Abre Oficina en Ecuador | Newswise

Cedars-Sinai Abre Oficina en Ecuador | Newswise

Newswise — LOS ANGELES (June 5, 2025) — Cedars-Sinai International ha abierto una oficina en Quito, Ecuador, aumentando el acceso a la atención de clase mundial para los pacientes ecuatorianos, y el fortalecimiento de los lazos con un socio clave de la salud de América del Sur. La nueva oficina será el primer punto de contacto…

Read More
Chen Institute Opens Public Registration for Symposium on AI Accelerated Science | Newswise

Chen Institute Opens Public Registration for Symposium on AI Accelerated Science | Newswise

Newswise — REDWOOD CITY, Calif., June 9, 2025 — The Tianqiao and Chrissy Chen Institute today announced that free registration to attend “AIAS 2025: the Chen Institute Symposium for AI Accelerated Science” on October 27-28th in San Francisco is now open at www.AIAS2025.org. Jennifer Doudna, Nobel Laureate in Chemistry, Li Ka Shing Chancellor’s Chair in Biomedical…

Read More
Could Electric Fields Supercharge Immune Attack on the Deadliest Form of Brain Cancer? | Newswise

Could Electric Fields Supercharge Immune Attack on the Deadliest Form of Brain Cancer? | Newswise

Newswise — LOS ANGELES — A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a brain tumor diagnosis with few available effective treatments. According to the National Brain Tumor Society, the average survival for patients diagnosed with glioblastoma is eight months. The study finds that…

Read More
Multiroute Administration of Wharton’s Jelly Mesenchymal Stem Cells in Chronic Complete Spinal Cord Injury: A Phase I Safety and Feasibility Study | Newswise

Multiroute Administration of Wharton’s Jelly Mesenchymal Stem Cells in Chronic Complete Spinal Cord Injury: A Phase I Safety and Feasibility Study | Newswise

BACKGROUND Newswise — Traumatic spinal cord injury (SCI) is a life-altering condition that results in long-term complications, including progressive neurodegeneration and cord atrophy. It presents a significant unmet medical need with extensive social and economic burdens. AIM To evaluate the safety and preliminary efficacy of allogeneic mesenchymal stem cells derived from Wharton’s jelly (WJ-MSCs) in…

Read More
Multiroute Administration of Wharton’s Jelly Mesenchymal Stem Cells in Chronic Complete Spinal Cord Injury: A Phase I Safety and Feasibility Study | Newswise

Dual-Target CAR T Cell Therapy Slows Growth of Aggressive Brain Cancer | Newswise

Newswise — CHICAGO – A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell therapy in nearly two-thirds of patients. While survival data is still accumulating, several patients lived 12 months or longer after receiving the investigational…

Read More